ArticleCureus2025
Survival Analysis of Breast Cancer Patients in Texas Using Classical and Machine Learning Methods.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Background Breast cancer is considered one of the most common cancers in women worldwide. In this study, we used an 11-year cohort of malignant breast cancer survival data in Texas to investigate the factors that might explain why some breast cancer patients live longer than others. Methods We performed standard survival analyses, including generating Kaplan‒Meier survival curves, using the log-rank test, and applying Cox proportional hazards regression to identify the unique features of breast cancer patients and determine the main factors influencing long-term survival. We also conducted a Random Survival Forest analysis for classification and prediction. Finally, we used Mahalanobis matching distance to estimate the average extended lifetime of patients in different groups. Results Our study found that stage, laterality, age, grade, subtypes, progesterone receptor status, the primary site of cancer, patient race, median household income, chemotherapy, systemic therapy, and surgery are significant factors, with stage being the most critical for predicting survival in breast cancer patients. Compared to individuals with localized-stage breast cancer, those with distant-stage cancer had a higher hazard ratio (15.869). We also observed that patients diagnosed at the localized stage had an average survival of approximately 67.34 months, compared to those diagnosed at the distant stage. Conclusion Policymakers should focus on promoting early diagnosis and screening, while also providing additional support to the elderly and those in disadvantaged circumstances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.